According to CoinMeta, VanEck Pharmaceutical ETF ( NASDAQ : PPH ) offers investment opportunities in low-cost, established pharmaceutical manufacturers with relatively low historical volatility, while Invesco Biotechnology and Genomics ETF ( NYSEMKT : PBE ) focuses on high-growth biotech companies, which come with higher costs. These two medical funds provide different options for investing in the life sciences sector. VanEck Fund is concentrated on major pharmaceutical giants, whereas Invesco Fund focuses on companies in the biotechnology and genomics fields, making selections based on factors such as revenue growth and price momentum. The expense ratio of VanEck Fund is 0.36%, significantly lower than Invesco Fund's 0.58%. In addition, VanEck Fund has made higher dividend payments in the past 12 months.